Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-16673 dose-escalation and expansion study in B-cell malignancies
2022-502157-33-00Phase 2Authorised
- Sponsor
- BeOne Medicines
- Start
- Sep 2023
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 17
01
Overview
Phase 2, open-label, single-arm trial of catadegbrutinib in B-cell malignancy, sponsored by BeOne Medicines. Planned start Sep 2023; status: authorised.
02
Drugs
catadegbrutinib
03
Conditions
B-cell malignancy
Beyond the preview
Go deeper on 2022-502157-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502157-33-00.